A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With Trastuzumab

Clinical trial NCT06681298 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06681298
Sponsor: xiaohua li
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Adenocarcinoma of the Esophagogastric Junction Perioperative Period

Start date: 2024-05-01
Primary completion: 2029-05-01
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.